Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining radiotherapy: the gut as an active target in Immuno-Oncology.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium.

The Lancet. Oncology·2026
Same author

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

JAMA oncology·2026
Same author

ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.

The Lancet. Respiratory medicine·2026

Related Experiment Video

Updated: Jul 13, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K

Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.

Tarek Assi1, Carine Ngo2, Matthieu Faron2,3

  • 1Sarcoma Unit, Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France. Tarek.assi@gustaveroussy.fr.

Current Treatment Options in Oncology
|October 16, 2023
PubMed
Summary

Pleomorphic liposarcoma (PLPS) treatment is based on other liposarcoma subtypes due to limited data. Newer therapies like eribulin show promise in advanced stages over traditional chemotherapy.

Keywords:
ChemotherapyLiposarcomaPleomorphicSarcomaSoft tissue

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K

Related Experiment Videos

Last Updated: Jul 13, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K

Area of Science:

  • Oncology
  • Sarcoma Research
  • Medical Therapeutics

Background:

  • Pleomorphic liposarcoma (PLPS) is a rare, high-grade soft tissue sarcoma.
  • Current therapeutic strategies are extrapolated from other liposarcoma subtypes.
  • Limited retrospective data exist, lacking specific guidelines for PLPS management.

Purpose of the Study:

  • To review current therapeutic approaches for pleomorphic liposarcoma.
  • To highlight the efficacy of specific systemic therapies in advanced PLPS.
  • To discuss the evolving landscape of soft tissue sarcoma treatment.

Main Methods:

  • Review of published retrospective data on PLPS treatment.
  • Comparison of conventional chemotherapy (doxorubicin, gemcitabine) with newer agents (eribulin, trabectedin).
  • Analysis of treatment outcomes in advanced-stage disease.

Main Results:

  • Conventional therapies (doxorubicin, gemcitabine) are standard for initial PLPS stages.
  • Eribulin and trabectedin demonstrate promising activity in advanced PLPS.
  • Retrospective data guide current oncological practice in the absence of specific guidelines.

Conclusions:

  • Novel systemic therapies offer potential benefits for advanced PLPS.
  • Further research and adapted clinical trials are needed for rare soft tissue sarcoma histotypes.
  • Understanding STS pathophysiology informs tailored treatment strategies.